PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34125421-0	2021	Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.	lisocabtagene maraleucel	32-56	CD19 molecule	Homo sapiens	72-76
34125421-1	2021	BACKGROUND AND OBJECTIVES: Lisocabtagene maraleucel (liso-cel) is a CD19-directed, defined composition, 4-1BB chimeric antigen receptor (CAR) T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	27-51	CD19 molecule	Homo sapiens	68-72
34125421-1	2021	BACKGROUND AND OBJECTIVES: Lisocabtagene maraleucel (liso-cel) is a CD19-directed, defined composition, 4-1BB chimeric antigen receptor (CAR) T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	27-51	nuclear receptor subfamily 1 group I member 3	Homo sapiens	137-140
34125421-1	2021	BACKGROUND AND OBJECTIVES: Lisocabtagene maraleucel (liso-cel) is a CD19-directed, defined composition, 4-1BB chimeric antigen receptor (CAR) T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	27-51	CD8a molecule	Homo sapiens	195-198
34125421-1	2021	BACKGROUND AND OBJECTIVES: Lisocabtagene maraleucel (liso-cel) is a CD19-directed, defined composition, 4-1BB chimeric antigen receptor (CAR) T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	27-51	CD4 molecule	Homo sapiens	204-207
34125421-1	2021	BACKGROUND AND OBJECTIVES: Lisocabtagene maraleucel (liso-cel) is a CD19-directed, defined composition, 4-1BB chimeric antigen receptor (CAR) T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	27-51	nuclear receptor subfamily 1 group I member 3	Homo sapiens	209-212
34216384-0	2021	Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.	lisocabtagene maraleucel	47-71	CD19 molecule	Homo sapiens	87-91
35156195-1	2022	Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor T-cell product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after 2 or more lines of systemic therapy.	lisocabtagene maraleucel	0-24	CD19 molecule	Homo sapiens	54-58
34699774-1	2021	Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product, with a CD3zeta activatory domain connected to 4-1BB costimulatory domain.	lisocabtagene maraleucel	0-24	CD19 molecule	Homo sapiens	53-57
34699774-1	2021	Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product, with a CD3zeta activatory domain connected to 4-1BB costimulatory domain.	lisocabtagene maraleucel	0-24	CD247 molecule	Homo sapiens	122-129
35619325-1	2022	The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	73-97	CD19 molecule	Homo sapiens	20-24
35619325-1	2022	The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	73-97	nuclear receptor subfamily 1 group I member 3	Homo sapiens	25-50
35619325-1	2022	The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	73-97	nuclear receptor subfamily 1 group I member 3	Homo sapiens	52-55
35610089-3	2022	Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, defined-composition, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	0-24	CD19 molecule	Homo sapiens	54-58
35610089-3	2022	Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, defined-composition, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	0-24	nuclear receptor subfamily 1 group I member 3	Homo sapiens	96-99
35610089-3	2022	Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, defined-composition, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	0-24	CD8a molecule	Homo sapiens	153-156
35610089-3	2022	Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, defined-composition, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	0-24	CD4 molecule	Homo sapiens	162-165
35610089-3	2022	Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, defined-composition, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells.	lisocabtagene maraleucel	0-24	nuclear receptor subfamily 1 group I member 3	Homo sapiens	167-170
35059997-2	2022	RECENT FINDINGS: Currently, four chimeric antigen receptor (CAR) T cell products are approved: axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, and brexucabtagene autoleucel.	lisocabtagene maraleucel	138-162	nuclear receptor subfamily 1 group I member 3	Homo sapiens	33-58
35059997-2	2022	RECENT FINDINGS: Currently, four chimeric antigen receptor (CAR) T cell products are approved: axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, and brexucabtagene autoleucel.	lisocabtagene maraleucel	138-162	nuclear receptor subfamily 1 group I member 3	Homo sapiens	60-63
32888407-1	2020	BACKGROUND: Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product.	lisocabtagene maraleucel	12-36	nuclear receptor subfamily 1 group I member 3	Homo sapiens	81-106
32888407-1	2020	BACKGROUND: Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product.	lisocabtagene maraleucel	12-36	nuclear receptor subfamily 1 group I member 3	Homo sapiens	108-111
34030548-1	2021	INTRODUCTION: Lisocabtagene Maraleucel (Liso-cel) is a second-generation Chimeric Antigen Receptor T-cell (CAR-T) therapy product targeting CD19.	lisocabtagene maraleucel	14-38	CD19 molecule	Homo sapiens	140-144
33970454-3	2021	Lisocabtagene maraleucel (liso-cel) is an investigational CAR T-cell therapy that has shown promising activity in this setting.	lisocabtagene maraleucel	0-24	nuclear receptor subfamily 1 group I member 3	Homo sapiens	58-61